astrazeneca
hit
by
drug
failur
share
in
angloswedish
drug
have
close
down
in
uk
trade
after
the
failur
of
it
iressa
drug
in
a
major
clinic
trial
the
lung
cancer
drug
did
not
significantli
prolong
surviv
in
patient
with
the
diseas
thi
setback
for
the
group
follow
the
reject
by
the
u
in
octob
of
it
anticoagul
pill
exanta
meanwhil
anoth
of
it
major
money
spinner
cholesterol
drug
crestor
is
face
mount
safeti
concern
thi
would
be
two
of
the
three
blockbust
drug
that
were
meant
to
power
the
compani
forward
fail
and
weve
got
risk
on
crestor
said
nick
turner
analyst
at
broker
jefferi
astrazeneca
had
hope
to
pitch
it
iressa
drug
against
rival
medicin
tarceva
but
iressa
prove
no
better
than
a
placebo
in
extend
live
in
the
trial
involv
patient
tarceva
made
by
osi
pharmaceut
genentech
and
roch
ha
alreadi
prove
to
be
success
in
help
prolong
the
life
of
lung
cancer
patient
aztrazeneca
ha
now
appoint
a
new
execut
director
to
the
board
john
patterson
will
be
in
charg
of
drug
develop
the
compani
said
mr
patterson
would
make
substanti
chang
to
the
clinic
organis
and
it
process
i
am
determin
to
improv
our
develop
and
regulatori
perform
restor
confid
in
the
compani
and
valu
to
sharehold
said
chief
execut
tom
mckillop
